# The Effect(s) of Sevelamer Carbonate (Renvela) on Atherosclerotic Plaque Inflammation Judged by FDG-PET Scan

> **NCT01238588** · NA · TERMINATED · sponsor: **Brigham and Women's Hospital** · enrollment: 24 (actual)

## Conditions studied

- Dialysis
- Cardiovascular Disease
- Atherosclerosis
- Inflammation
- Hyperphosphatemia

## Interventions

- **DRUG:** Sevelamer Carbonate (Renvela)

## Key facts

- **NCT ID:** NCT01238588
- **Lead sponsor:** Brigham and Women's Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-06-10
- **Primary completion:** 2016-04-08
- **Final completion:** 2016-04-08
- **Target enrollment:** 24 (ACTUAL)
- **Why stopped:** The study stopped due to lack of funding.
- **Last updated:** 2017-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01238588

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01238588, "The Effect(s) of Sevelamer Carbonate (Renvela) on Atherosclerotic Plaque Inflammation Judged by FDG-PET Scan". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01238588. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*